Samuele Maramai, Mario Saletti, Marco Paolino, Germano Giuliani, Jessica Cazzola, Paolo Spaiardi, Francesca Talpo, Maria Frosini, Alice Pifferi, Marco Ballarotto, Andrea Carotti, Federica Poggialini, Chiara Vagaggini, Elena Dreassi, Gianluca Giorgi, Giulio Dondio, Andrea Cappelli, Gerardo Rosario Biella, Maurizio Anzini
Riluzole, the first clinically approved treatment for amyotrophic lateral sclerosis (ALS), represents a successful example of a drug endowed with a multimodal mechanism of action. In recent years, different series of riluzole-based compounds have been reported, including several agents acting as Multi-Target-Directed Ligands (MTLDs) endowed with neuroprotective effects. Aiming at identical twin structures inspired by riluzole (2a-c), a synthetic procedure was planned, but the reactivity of the system took a different path, leading to the serendipitous isolation of benzo[b][1,4]thiazepines 3a-c and expanded intermediates N-cyano-benzo[b][1,4]thiazepines 4a-c, which were fully characterized...
August 13, 2024: Bioorganic & Medicinal Chemistry